Related Experiment Video
Updated: Aug 19, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
Published on: December 1, 2023
Natalizumab (Tysabri) for relapsing multiple sclerosis
Natalizumab (Tysabri), a selective adhesion molecule inhibitor, decreases the number of relapses and new brain lesions in patients with MS. Administered IV every 4 weeks, it is usually well tolerated, but anaphylaxis can occur and persistent neutralizing antibodies were reported in 6% of patients. No comparisons to other MS treatments and no data concerning its effect on progression of disability are currently available.
Natalizumab (Tysabri), a selective adhesion molecule inhibitor, decreases the number of relapses and new brain lesions in patients with MS. Administered IV every 4 weeks, it is usually well tolerated, but anaphylaxis can occur and persistent neutralizing antibodies were reported in 6% of patients. No comparisons to other MS treatments and no data concerning its effect on progression of disability are currently available.
Related Concept Videos
Respiratory Syncytial Virus Disease
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Multiple Sclerosis l: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
